Androgen replacement therapy and prostate safety

European Urology

Volumn 41, Issue 2, 2002, Pages 113-120

  Morales, Alvaro ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Androgens; Prostate cancer; Prostate safety; Testosterone

Indexed keywords

BOLDENONE; FOLLITROPIN; GROWTH HORMONE; HEMOGLOBIN; LIPID; PRASTERONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN THERAPY; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DRUG CONTRAINDICATION; EVIDENCE BASED MEDICINE; FLUID RETENTION; GYNECOMASTIA; HEMATOCRIT; HORMONE DEFICIENCY; HUMAN; HYPOGONADISM; LIPID BLOOD LEVEL; LIVER DISEASE; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; REVIEW; SLEEP APNEA SYNDROME; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; TUMOR PROMOTION;

EID: 0036487661     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(01)00039-2     Document Type: Article

References (54)

1. Morales A, Heaton JPW, Carson CC. Andropause: A misnomer for a true clinical entity. J Urol 2000;163:705-12.
2. Nickel JC, Morales A, Condra M, Fenemore J, Surridge DHC. Endocrine dysfunction and impotence: Incidence, significance and cost-effective screening. J Urol 1984;132:40-3.
3. Morley JE. Andropause, testosterone treatment and quality of life in aging men. Cleveland Clin J Med 2000;67:880-2.
4. Heinemann LAJ, Saad F, Thiele K, Wood-Duphinee S. The aging male's symptom rating scale: Cultural and linguistic validation into English. Aging Male 2001;4:14-22.
5. Kropman RF, Verdijk RM, Lyklama AAB, Nijeholt A, Roelfsma F. Routine endocrine screening in impotence: Significance and cost-effectiveness. Int J Impotence Res 1991;3:87-91.
6. Vermeulen A. Routine endocrine screening in impotence: Significance and cost effectiveness. Editorial Int J Impotence Res 1991;3: 85-6.
7. Morales A, Johnston B, Heaton JWP, Lundie M. Testosterone supplementation in hypogonadal impotence: Assessment of biochemical measurements and therapeutic outcomes. J Urol 1997;157:849-54.
8. Tremblay RR. Practical consequences of the validation of a mathematical model in assessment of partial androgen deficiency in the aging male using bioavailable testosterone. Aging Male 2001;4:23-9.
9. Vermeulen A, Verdonk L, Kaufman JL. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72.
10. Bagatell C, Bremner WJ. Androgens in men - Uses and abuses. New Engl J Med 1996;334:707-14.
11. Gooren UG. Testosterone undecanoate. J Androl 1994;15:212-5.
12. Kamischke A, Venherm S, Plöger D, von Eckardstein S, Nieschlag E. Intramuscular testosterone undecanoate and northisterone in a clinical trial for men contraception. J Clin Endocrinol Metab 2001;86:303-9.
13. Wilson JD, Griffin JE. The use and misuse of androgens. Metabolism 1980;9:1278-96.
14. Bagatell CJ, Bremner WJ. Androgen and progestagen effects on plasma lipids. Prog Cardiovasc Dis 1995;38:255-9.
15. Crook D. Androgens and the risk of cardiovascular disease. Aging Male 2000;3:190-5.
16. Webb CM, McNeil JG, Hayward CS, de Zeigler D, Collins P. Effect of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999;100:1690-6.
17. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficiency and safety of permeation enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999;84:3469-78.
18. Sandblom RE, Matsumoto AM, Schoene RB et al. Obstructive sleep apnea syndrome induced by testosterone administration. N Engl J Med 1983;308:508-12.
19. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG, Strom BL. Effect of testosterone on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84:1966-72.
20. Davies P, Eaton CL. Regulation of prostate growth. J Endocrinol 1991;131:5-9.
21. Meikle WA, Stephenson RA, Lewis CM, Middleton RG. Effects of age and sex hormones on transition and peripheral zone volumes in benign prostatic hyperplasia in twins. J Clin Endocrinol Metab 1997;82:571-5.
22. Thomas JA, Keenan EJ. Effects of estrogens on the prostate. J Androl 1994;15:97-100.
23. Behere HM. Prostate volume in treated and untreated hypogonadal men in comparison to age-matched controls. Clin Endocrinol 1994;40:341-6.
24. Douglas TH, Connelly RR, McLeod DG, Erickson SJ, Barren III R, Murphy GP. Effect of exogenous testosterone replacement on prostate specific antigen and prostate specific membrane antigen levels in hypogonadal men. J Surg Oncol 1995;59:246-50.
25. Tenover JL. Androgen administration to aging men. Endocrinol Metab Clin NA 1997;23:877-86.
26. Tenover JL. Androgen deficiency in aging men. Aging Male 1998;1(Suppl 1):16-21.
27. Nobel R. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 1977;37:1929-34.
28. Gann PH, Hennekens CH, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-25.
29. Slater S, Oliver RTD. Testosterone: Its role in the development of prostate cancer and potential risks from use as hormone replacement therapy. Drugs Aging 2000;17:431-9.
30. Shanayfelt T, Husein R, Bebkey G, Mantzoras C. Hormonal predictors of prostatic cancer: A meta analysis. J Clin Oncol 2000;18:847-53.
31. Andersson S-O, Wolk A, Bergström R, Adami H-O, Göran E, Englund A, Nyrén O. Body size and prostate cancer: A 20 year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 1997;89:385-9.
32. Ross RK, Henderson BE. Do diet and androgens alter prostate cancer risk via a common etiological pathway? J Natl Cancer Inst 1994;86:252-4.
33. Meikle A, Arver S, Dobs AS, Adolfonson J, Sanders SW, Middleton RG, Stephenson RA, Hoover DR, Rajaram L, Mazer NA. Prostate size in hypogonadal men treated with a non-scrotal permeationenhanced testosterone transdermal system. Urology 1997;49:191-6.
34. Curran MJ, Bihrle W. Dramatic rise in prostatic specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 1999;53:423.
35. Carter HB, Pearson JD, Metter EJ, Chan DW, Andres R, Fozard JL, Rosner W, Walsh PC. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 1995;27: 25-30.
36. Hulka BS, Hammond JE, DiFernando G. Serum hormone levels among patients with prostatic carcinoma or benign prostatic hyperplasia and clinic controls. Prostate 1987;11:171-82.
37. Harper ME, Pierrepoint CG, Griffiths K. Carcinoma of the prostate: Relationship of pre-hormone levels to survival. Eur J Cancer Clin Oncol 1984;20:451-77.
38. Prout GRJ, Brewer WR. Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer 1967;20:1871-5.
39. Morales A, Connolly J, Burr R, Bruce AW. The use of radioactive phosphorous to treat bone pain in metastatic carcinoma of the prostate. Can Med Assoc J 1970;103:372-5.
40. Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res 1999;59:4161-7.
41. Santner SJ, Albertson B, Zhang GY et al. Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects. J Clin Endocrinol Metab 1998;83:2104-9.
42. Guess HA, Friedman GD, Sadler MC. 5α-reductase activity and prostate cancer: A case control study using stored sera. Cancer Epidemiol Biomarkers Prev 1997;6:21-6.
43. Bartsch W, Steins P, Becker H. Hormone blood levels in patients with prostatic carcinoma and their relation to the type of carcinoma growth differentiation. Eur Urol 1977;3:47-52.
44. Lam PL, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of transdermal dehydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 2001;89:4078-88.
45. Voermans C, Condon MS, Bosland MC. Growth inhibition by dehydroepiandrosterone of human prostate cancer cell lines and primary epithelial cultures of rat prostate carcinomas. Proc Am Assoc Cancer Res Annual Meeting 1996;37.
46. Comstock GW, Gordon GB, Hsing AW. The relationship of dehydroepiandrosterone and its sulfate to subsequent cancer of the prostate. Cancer Epidemiol Biomarkers Prev 1993;2:219-21.
47. Schatzel G, Reiter WJ, Thurridl T, Walmuller J, Roden M, Soregi S, Madersbacher S. Endocrine patterns in patients with benign and malignant prostate diseases. Prostate 2000;44:219-24.
48. Jones JA, Nguyen A, Straub M, Leidic RB, Veech RL, Wolf S. Use of DHEA in a patient with advanced prostate cancer: A case report and review. Urology 1997;50:784-8.
49. Martin-Du Pan RC. Are the hormones of youth carcinogenic? Ann Endocrinol (French) 1999;60:392-7.
50. Grimberg A, Cohen P. Growth hormone and prostate cancer: Guilty by association? J Endocrinol Invest 1999;22(Suppl 5):64-73.
51. LeRoith D. Clinical guidelines for treatment with growth hormone in the aging individual. Aging Male 2001;4(Suppl 1):44-5.
52. Consensus. Critical evaluation of the safety of recombinant human growth hormone administration: Statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 2001;86:1868-71.
53. Tremblay RR, Morales A. Canadian practice recommendations for screening, monitoring and treating men affected by andropause or partial androgen deficiency. Aging Male 1998;1:213-8.
54. Morales A, Lunenfeld B. Draft Recommendations of the International Society for the Study of the Aging Male on Androgen Replacement Therapy. Aging Male 2001;4:151-62.